Combination study with the checkpoint inhibitor Yervoy® (indication advanced solid tumors)

The study titled “A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients with Advanced Solid Malignancies” is conducted by MD Anderson Cancer Center (MD Anderson). MOLOGEN provides the Immune Surveillance Reactivator (ISR) lefitolimod and funds the study. Around 50-60 patients will participate in MD Anderson Cancer Center in Houston, Texas, USA. Patient recruitment began in July 2016 and is expected to be completed at the beginning of 2018.

The primary aim of the study is to determine the best tolerable dose for lefitolimod in combination with Yervoy®. The safety of this combination therapy will also be investigated and an expansion phase is planned to evaluate the efficacy of this combination therapy.